Oramed Pharmaceuticals (ORMP) Proxy filing summary

Executive summary

• Annual Meeting scheduled for August 1, 2024, with voting on director re-election, executive compensation, and auditor ratification.

• Record date for voting eligibility is June 12, 2024; 40,628,924 shares outstanding.

• Proxy materials available online and by request; voting can be done in person, by mail, or electronically.

Voting matters and shareholder proposals

• Proposal 1: Re-election of seven directors to serve until the next annual meeting.

• Proposal 2: Non-binding advisory vote on compensation of Named Executive Officers.

• Proposal 3: Ratification of Kesselman & Kesselman (PwC Israel) as independent auditors for 2024.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of seven members, all nominated for re-election; includes a mix of executive and independent directors.

• Board committees: Audit, Compensation, and Nominating, all comprised of independent directors.

• Annual board and committee evaluations conducted for continuous improvement.

• Board diversity matrix disclosed; commitment to diverse backgrounds and skills.

• Code of Ethics and anti-hedging policy in place for directors, officers, and employees.